CNS Pharmaceuticals's total assets for Q3 2024 were $7.41M, an increase of 200.06% from the previous quarter. CNSP total liabilities were $4.06M for the fiscal quarter, a -40.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.